Clinical Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms

Rinzivillo, Maria; Partelli, Stefano; Prosperi, Daniela; Capurso, Gabriele; Pizzichini, Patrizia; Iannicelli, Elsa; Merola, Elettra; Muffatti, Francesca; Scopinaro, Francesco; Schillaci, Orazio; Salgarello, Matteo; Falconi, Massimo; Fave, Gianfranco Delle; Panzuto, Francesco

doi:10.1634/theoncologist.2017-0278

Cited by 42 publications

(31 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given their high proliferative activity and low expression of SSTRs, poorly differentiated NETs are commonly imaged by 18 F‐fluorodeoxyglucose PET/CT. In well‐differentiated NETs 18 F‐fluorodeoxyglucose PET uptake can correlate negatively with prognosis; however, the use of this imaging modality is not routinely recommended …”

Section: Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Gastroenteropancreatic Neuroendocrine Tumors

Cives

Strosberg

2018

CA A Cancer J Clinicians

457

411

View full text Add to dashboard Cite

Neuroendocrine tumors (NETs) are heterogeneous malignancies arising from the diffuse neuroendocrine system. They frequently originate in the gastroenteropancreatic (GEP) tract and the bronchopulmonary tree, and their incidence has steadily increased in the last 3 decades. Fundamental biologic and genomic differences underlie the clinical heterogeneity of NETs, and distinct molecular features characterize NETs of different grades and different primary sites. Although surgery remains the cornerstone of treatment for localized tumors, systemic treatment options for patients with metastatic NETs have expanded considerably. Somatostatin analogs have demonstrated both antisecretory and antitumor efficacy. Peptide receptor radionuclide therapy with lutetium‐177 dotatate (177Lu‐DOTATATE) has been approved for advanced GEP‐NETs. The antitumor activity of everolimus has been demonstrated across a wide spectrum of NETs, and the antiangiogenic agent sunitinib has been approved for pancreatic NETs (pNETs). Chemotherapy with temozolomide and capecitabine has recently demonstrated an unprecedented prolongation of progression‐free survival in a randomized trial of pNETs. Multiple retrospective series have reported the efficacy of liver‐directed therapies both for palliating symptoms of hormone excess and for controlling tumor growth. Telotristat, an oral inhibitor of tryptophan hydroxylase, has been shown to reduce diarrhea in patients with carcinoid syndrome. Defining the therapeutic algorithm and identifying biomarkers predictive of response to treatments are among the main priorities for the next decade of research in the NET field.

show abstract

Section: Diagnosismentioning

confidence: 99%

“…In well-differentiated NETs 18 F-fluorodeoxyglucose PET uptake can correlate negatively with prognosis; however, the use of this imaging modality is not routinely recommended. 91,92…”

Section: Diagnosismentioning

confidence: 99%

Gastroenteropancreatic Neuroendocrine Tumors

Cives

Strosberg

2018

CA A Cancer J Clinicians

457

411

View full text Add to dashboard Cite

show abstract

“…Indeed, in the last few years, the role of 18F-FDG PET/CT in these neoplasms has emerged as an important tool to define tumor aggressiveness and give relevant prognostic information especially in the management of G3 NEN [7,37]. In fact, it has been well demonstrated that 18F-FDG PET/CT has a high diagnostic accuracy to identify progression of disease with unfavorable clinical outcomes in patients with advanced GEP NEN [38]. In addition, its recently emerging the potential role of 18F-FDG PET/CT in predicting response to PRRT in advanced NEN [39][40][41].…”

Section: Imaging Investigationsmentioning

confidence: 99%

Tumor Heterogenity in Gastro-Entero-Pancreatic Neuroendocrine Neoplasia

Rinzivillo

Panzuto

2021

Endocrines

Self Cite

View full text Add to dashboard Cite

Owing to the rarity and the biological and clinical heterogeneity of gastroenteropancreatic neuroendocrine neoplasia (GEP NEN), the management of these patients may be challenging for physicians. This review highlights the specific features of GEP NEN with particular attention on the role of Ki67 heterogeneity, the potential prognostic role of novel radiological techniques, and the clinical usefulness of functional imaging, including 68Ga-DOTA-SST PET/CT and 18F-FDG PET/CT. Understanding these specific features may help to plan proper and tailored follow-up programs and therapeutic approaches.

show abstract

“…Although its usefulness in NET is limited due to the low glycolytic activity of these cancer cells, positive 18 FDG imaging often foreshadows a more aggressive disease course. 24…”

Section: Radioligand Theranostics For Somatostatin Receptorpositive Netsmentioning

confidence: 99%

Theranostics: Cancer imaging and therapy using injectable radionuclide-labeled ligands

Redfern¹

2020

PPIJ

View full text Add to dashboard Cite

Introduction: the foundation stone of radioligand theranostics (RT)During part of World War 2 and in the immediate years thereafter, Dr Saul Hertz at Massachusetts General Hospital conducted his trailblazing research on the medical applications of artificial radioactivity, the process of making non-radioactive atoms radioactive by means of a particle accelerator. 1 Collaborating with several physicists, Hertz used a cyclotron to generate radioactive 130 I and 131 I and subsequently utilized these nascent isotopes to diagnose and treat patients with thyroid carcinoma. In so doing, Hertz inaugurated the era of nuclear medicine and targeted precision cancer therapy and created the first Food and Drug Administration (FDA)-approved (in 1951) radiopharmaceutical for the treatment of thyroid cancer. Targeting the sodium-iodine symporter in patients with thyroid carcinoma remains a pillar of nuclear medicine to this day. 2 Now, more than 80 years later, radiopharmaceutical development has taken giant leaps forward with far-reaching therapeutic implications for many other cancer

show abstract

Clinical Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms

Abstract: The findings of the present study may help physicians dealing with advanced neuroendocrine neoplasms to select patients for whom F-fluorodeoxyglucose positron emission tomography is useful to predict poor clinical outcome.

Cited by 42 publications

References 35 publications

Gastroenteropancreatic Neuroendocrine Tumors

Gastroenteropancreatic Neuroendocrine Tumors

Tumor Heterogenity in Gastro-Entero-Pancreatic Neuroendocrine Neoplasia

Theranostics: Cancer imaging and therapy using injectable radionuclide-labeled ligands

Contact Info

Product

Resources

About